There is increasing evidence that FXa exerts non-hemostatic cellular effects, is mediated primarily through protease-activated receptor 1, and is associated with pathophysiological conditions such as atherosclerosis, inflammation, and fibrosis. This evidence concerns the gene F2R and atherosclerosis.